Phio Pharmaceuticals (PHIO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Phio Pharmaceuticals Completes Enrollment In Second Cohort In Phase 1b Dose-Escalating Clinical Study
BenzingaNov 19 07:48 ET
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
newsfileNov 19 07:45 ET
Phio Pharma Shares Are Trading Higher. The Company Reported Q3 Financial Results.
BenzingaNov 15 08:36 ET
Express News | Phio Pharma Shares Are Trading Higher. The Company Reported Q3 Financial Results
BenzingaNov 15 08:36 ET
Phio Pharma Q3 2024 GAAP EPS $(1.54) May Not Be Comparable To $(4.14) Estimate
BenzingaNov 14 17:50 ET
Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:54 ET · Announcements

Comments

Jaguar8

Dec 3 06:46

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Tuesday, 3rd December at 7:45 am
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST
Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silenci...

1

Jaguar8

Nov 19 06:49

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tu...

Jaguar8

Nov 7 09:37

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patient...

Stock_Drift

Oct 16 09:13

Low Float Ticks. 10:12am 10/16

$Allarity Therapeutics (ALLR.US)$ $PainReform (PRFX.US)$ $Helius Medical Technologies (HSDT.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $Phio Pharmaceuticals (PHIO.US)$ $Entero Therapeutics (ENTO.US)$ $Vaccinex (VCNX.US)$ $Bone Biologics (BBLG.US)$ $Wang & Lee Group (WLGS.US)$ $Nuburu (BURU.US)$ $Quoin Pharmaceuticals (QNRX.US)$

1

3

Jaguar8

Oct 16 07:02

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to pote...

1

PHIO Phio Pharmaceuticals

Trade Overview

Capital Trend

News

Comments